Get the Stockscreener App
0.2407
1.89%
-0.00525
Plus Therapeutics Inc stock is traded at $0.2407, with a volume of 209.56K.
It is down -1.89% in the last 24 hours and down -25.61% over the past month.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, commercializing and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
See More
Previous Close:
$0.2459
Open:
$0.2416
24h Volume:
209.56K
Relative Volume:
0.02
Market Cap:
$41.39M
Revenue:
$5.21M
Net Income/Loss:
$-26.35M
P/E Ratio:
-0.1875
EPS:
-1.2835
Net Cash Flow:
$-20.84M
1W Performance:
+0.06%
1M Performance:
-25.61%
6M Performance:
-60.91%
1Y Performance:
-83.59%
1-Day Range:
$0.2388
$0.2459
1-Week Range:
$0.231
$0.254
52-Week Range:
$0.1634
$1.77
Plus Therapeutics Inc Stock (PSTV) Company Profile
Name
Plus Therapeutics Inc
Sector
Industry
Phone
737.255.7194
Address
4200 MARATHON BLVD., AUSTIN, TX
Compare PSTV vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PSTV
Plus Therapeutics Inc
|
0.2413 | 42.18M | 5.21M | -26.35M | -20.84M | -1.2835 |
VRTX
Vertex Pharmaceuticals Inc
|
451.39 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
754.55 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
329.82 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
687.64 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.26 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-03-26 | Initiated | Lake Street | Buy |
| Sep-03-25 | Upgrade | D. Boral Capital | Hold → Buy |
| Mar-17-25 | Initiated | D. Boral Capital | Buy |
| Jan-25-21 | Initiated | Ladenburg Thalmann | Buy |
| Oct-16-20 | Initiated | Maxim Group | Buy |
Plus Therapeutics Inc Stock (PSTV) Latest News
Plus Therapeutics Adds Industry Veteran Ronald Andrews to Board - TipRanks
Plus Therapeutics appoints Ronald A. Andrews to board following director resignation - Investing.com
Ronald Andrews joins Plus Therapeutics (NASDAQ: PSTV) board - Stock Titan
Plus Therapeutics appoints Ron Andrews to board of directors By Investing.com - Investing.com India
Plus Therapeutics Appoints Diagnostics and Molecular Diagnostics Industry Leader Ron Andrews to its Board of Directors - Yahoo! Finance Canada
Aug Action: Will Plus Therapeutics Inc benefit from rising consumer demandPortfolio Return Report & Real-Time Volume Trigger Notifications - baoquankhu1.vn
If You Invested $1,000 in Grace Therapeutics, Inc (GRCE) - Stock Titan
PSTV Stock Price, Quote & Chart | PLUS THERAPEUTICS INC (NASDAQ:PSTV) - ChartMill
PSTV Analyst Rating: D. Boral Capital Maintains Buy Rating | PST - GuruFocus
Plus Therapeutics Presents Analysis Showing CNSide May Reduce Leptomeningeal Metastases Costs by 40% - National Today
Plus Therapeutics (PSTV) Study Highlights Cost Benefits of Early LM Detection - GuruFocus
Plus Therapeutics Study Shows Early Detection Can Reduce Healthcare Costs - Intellectia AI
Plus Therapeutics to Present New Analysis at ISPOR Showing CNSide® May Reduce Leptomeningeal Metastases Healthcare Costs by 40% - The Manila Times
symbol__ Stock Quote Price and Forecast - CNN
Analysts Are Bullish on These Healthcare Stocks: Ascendis Pharma (ASND), Plus Therapeutics (PSTV) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Aclaris Therapeutics (ACRS) and Plus Therapeutics (PSTV) - The Globe and Mail
Plus Therapeutics Sets 2026 Virtual Annual Stockholder Meeting - The Globe and Mail
Plus: Q4 Earnings Snapshot - theheraldreview.com
Plus Therapeutics (PSTV) Beats EPS Expectations Despite Revenue Decline - GuruFocus
Plus Therapeutics (PSTV) Surpasses Q4 Revenue Expectations - GuruFocus
Plus Therapeutics Reports 2025 Results, Advances CNSide Commercial Rollout and REYOBIQ Clinical Program with 2026 Milestones - Minichart
PLUS THERAPEUTICS, INC. Files Form 8-K with SEC Detailing Shareholder Director Nomination Procedures and Company Information - Minichart
Plus Therapeutics, Inc. 2025 Annual Report: Precision Radiopharmaceuticals and CNS Cancer Innovations - Minichart
Plus Therapeutics (PSTV) Reports Break-Even Earnings for Q4 - Yahoo Finance
Plus: Q4 Financial Overview - Bitget
Plus Therapeutics Reports 2025 Results, Business Progress and 2026 Anticipated Milestones for REYOBIQ Clinical Program and CNSide Commercial Rollout - Bitget
Plus Therapeutics 2025 net loss widens - TradingView
[8-K] PLUS THERAPEUTICS, INC. Reports Material Event | PSTV SEC FilingForm 8-K - Stock Titan
Plus Therapeutics 10-K: $5.21M Grant Revenue, Net Loss $0.29 EPS - TradingView
Plus Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Plus Therapeutics (NASDAQ: PSTV) updates CNS oncology pipeline and CNSide - Stock Titan
Plus Therapeutics (PSTV) widens 2025 loss but strengthens cash and CNS programs - Stock Titan
Plus Therapeutics Reports 2025 Results, Business Progress and 2026 Anticipated Milestones for REYOBIQ™ Clinical Program and CNSide® Commercial Rollout - The Manila Times
Plus Therapeutics Reports 2025 Results, Business Progress - GlobeNewswire
Plus Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
PSTV Earnings History & Surprises | EPS & Revenue Results | PLUS THERAPEUTICS INC (NASDAQ:PSTV) - ChartMill
Plus Therapeutics drops 5%, files prospectus for 17M share secondary offering - MSN
Can Plus Therapeutics Inc. stock deliver strong Q4 earningsEarnings Miss & Verified Short-Term Trading Plans - Naître et grandir
[RW] PLUS THERAPEUTICS, INC. SEC Filing - Stock Titan
Plus Therapeutics Secures National Coverage Agreement with Humana for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer - Stocktwits
PSTV SEC FilingsPlus Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
138,897,548 Common Stock of Plus Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 28-FEB-2026. - marketscreener.com
Certain Warrants of Plus Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 28-FEB-2026. - marketscreener.com
Certain Restricted Stock Units of Plus Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 28-FEB-2026. - marketscreener.com
Lake Street Sticks to Their Buy Rating for Plus Therapeutics (PSTV) - The Globe and Mail
Plus Therapeutics (PSTV) CFO granted RSUs and stock options package - Stock Titan
PLUS Therapeutics (PSTV) CEO receives large RSU and stock option grants - Stock Titan
PLUS THERAPEUTICS, Inc.Common Stock (NQ: PSTV - The Chronicle-Journal
Plus Therapeutics Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ - Bitget
Plus Therapeutics, Inc. Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ - marketscreener.com
Plus Therapeutics (PSTV) Gains New CPT Code for Innovation in Br - GuruFocus
Plus Therapeutics Inc Stock (PSTV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.99%
3.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):